1[1]Memarzadeh S, Berek JS. Advances in the management of epithelial ovarian cancer[J]. J Repord Med, 2001, 46(7): 621～629
2[2]Bodurka-Bevers D, Sun CC, Gershenson MD. Pharmacoeconomic considerations in treating ovarian cancer [J]. Pharmacoeconomics, 2000, 17(2): 133～150
3[3]Landis SH, Murray T, Bolden S, et al. Cancer statistics1 1998[J]. CA Cancer J Clin, 1998, 48(6): 3～29
4[4]Nahhas WA. Ovarian cancer. Current outlook on the deadly disease [J]. Postgrad Med, 1997, 102(3): 112～120
5[5]Markman M, Hoskins W. Responses to "salvage" chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population[J]. J Clin Oncol, 1992,10(4):513～514
6[6]Cremers GJ. Bolis G, Gone M, et al. Topetecan, an active drug in the second-line treatment of epithelial ovarian cancer,results of a large European phase 2 study [J]. J Clin Oncol,1996, 14(12): 3056～3061
7[7]Thigpen JT, Blessing JA, Ball H, et al. Phase Ⅱ trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study[J]. J Clin Oncol, 1994, 12(9): 1748～1753
8[8]Coeffic D. Paclitaxel, Topetecan and Cisplantin combination chemotherapy in advanced ovarian cancer [J]. Proc Annu Meeting Soc Gynecol Oncol, 2000, 19:1601
9[9]Hall JB, Higgins RV, Naumaun RW. Phase 2 study of Topotecan and Cisplatin combination chemotherapy in stage 3/4 of recurrent endonetnial cancer[J]. Proc Annu Meeting Soc Gynecol Oncol, 2000, 19:1618
10[10]Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds [J]. Gynecol Oncol,1990, 36(2): 207～211
